Daratumumab and isatuximab, FDA-approved anti-CD38 antibodies, kill MM cancer cells via Fc-dependent immune effector mechanisms, i.e., complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. The gene discussed is CD38; the disease is Miyoshi myopathy.